National Health Investors (NHI)
(Delayed Data from NYSE)
$64.78 USD
-0.19 (-0.29%)
Updated May 28, 2024 04:00 PM ET
After-Market: $64.81 +0.03 (0.05%) 6:20 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
National Health Investors (NHI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$63.86 | $73.00 | $54.00 | -1.71% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for National Health Investors comes to $63.86. The forecasts range from a low of $54.00 to a high of $73.00. The average price target represents a decline of 1.71% from the last closing price of $64.97.
Analyst Price Targets (7 )
Broker Rating
National Health Investors currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, four are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/15/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
3/11/2024 | BMO Capital Markets | John P Kim | Hold | Strong Buy |
2/26/2024 | Wedbush Securities | Richard Anderson | Hold | Strong Buy |
9/28/2023 | Berenberg Bank | Tao Qiu | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $63.86 |
LT Growth Rate | NA |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 152 of 252 |
Current Quarter EPS Est: | 1.09 |